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Background: The development of hormone-dependent cancers, including endometrial carcinomas, in great part may be mediated 
by the genotoxic effects of estrogen metabolites, among which 4-hydroxyestradiol (4OHE2) is characterized by the most prominent 
DNA-damaging properties. It is assumed that the individual sensitivity to the 4OHE2 may determine the predisposition to endo-
metrial cancer (EС). Aim: To analyze the sensitivity of peripheral blood lymphocytes (PBLs) of EC patients to the 4OHE2 and 
to evaluate the repair efficiency of 4OHE2-induced DNA damage. Materials and Methods: The study was performed on the PBLs 
of 53 EC patients and 20 healthy women. The level of DNA damage was measured using the comet assay and was expressed as % 
tail DNA. The DNA repair efficiency (%) was evaluated by determining the ratio between the amount of repaired DNA damage 
and the level of 4OHE2-induced damage that appeared after incubation of PBLs with 4OHE2. Results: In PBLs of EC patients, 
a higher level of 4OHE2-induced DNA damage (32.0 ± 2.2% tail DNA) and lower DNA repair efficiency (34.0 ± 4.5%) was ob-
served compared to PBLs of healthy women (22.3 ± 2.3% tail DNA and 48.8 ± 4.5%, respectively). PBLs of EC patients with deep 
tumor invasion of myometrium were characterized by more prominent decrease of DNA repair than those with less invasive tumor 
(< ½ of myometrium) (20.9 ± 7.8 and 43.7 ± 6.7%, respectively). Furthermore, lower DNA repair efficiency was detected in the 
PBLs of EC patients with a family history of cancer compared to this parameter in patients with sporadic tumors (20.9±7.8 and 
47.1 ± 5.5%, respectively). Conclusion: The PBLs of EC patients are characterized by increased sensitivity to the genotoxic ef-
fect of 4OHE2 and reduced repair efficiency regarding 4OHE2-induced DNA damage. A lower level of DNA repair is observed 
in EC patients with deep tumor myometrial invasion and a family history of cancer.
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Numerous studies have established that the ge-
nome of tumor cells is constantly exposed to a vari-
ety of effects that are realized with increased speed 
as genetic abnormalities [1]. The latter manifest 
themselves at different levels of the genome orga-
nization and occur both in individual nucleotides 
and in chromosomes. Present knowledge suggests 
that the genome instability is not only a key sign but 
also a driving force of carcinogenesis which causes 
intra-tumoral heterogeneity and progression of the 
neoplasm [2, 3]. A number of studies have shown that 
in addition to tumor cells, the destabilization of the ge-
nome is also observed in somatic non-malignant cells 
of cancer patients, in particular, in peripheral blood 
lymphocytes (PBLs) [4–7]. It is believed that the level 
of genome instability is determined by a combination 
of various factors, among which the individual sensitiv-
ity to genotoxic agents and the efficiency of DNA repair 
may be of considerable importance [8, 9].
There is an assumption that the degree of genome 
instability in the cells of the body is affected by the 
peculiarities of estrogen metabolism. It is known 
that metabolic transformations of estrogens occur 
through their oxidation to highly active electrophilic 
intermediates — catechol estrogens, quinones and 
semiquinones, which have genotoxic properties [10]. 
Estrogen metabolites are able to directly bind to DNA, 
leading to the appearance of apurinic sites, or to enter 
into redox cycling, generating radical oxygen species, 
which cause various DNA damages. Among catechol 
estrogens, the highest genotoxicity is inherent 
to 4-hydroxyestradiol (4OHE2), which is produced 
by cytochrome CYP 1B1 [10, 11]. It has been es-
tablished that endometrial cancer (EC) patients are 
characterized by the disturbance of the ratio of cir-
culating estrogen metabolites in the blood and the 
predominance of 4OHE2 among them [12]. Genotoxic 
impact of estrogen metabolites on various cell types, 
including cancer cell lines, has been the subject of ac-
tive study over the past few years [13–15]. However, 
the effect of 4OHE2 on somatic non-malignant cells 
of EC patients, in particular, on PBLs remains insuf-
ficiently studied. The importance of such studies is that 
elucidation of the mechanisms of action for estrogen 
metabolites will allow both to broaden the under-
standing of the pathogenesis of hormone-dependent 
tumors, including EC, and to evaluate the contribution 
of 4OHE2 to the genome instability of EC cells.
The latter may be considerably important for 
identifying women with a hereditary predisposition 
to EC. It is known that the occurrence of EC can 
be associated with hereditary syndromes caused 
by germinal mutations in tumor suppressor genes, in-
cluding the mismatch repair genes in Lynch syndrome 
and the PTEN gene in Cowden syndrome [16]. At the 
same time, to date, it has been found that hereditary 
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predisposition to EC can also be provoked by other, 
not yet fully clarified molecular mechanisms [17, 18]. 
One can assume that inherited hypersensitivity to es-
trogen metabolites can contribute to predisposition 
to EC. Therefore, the search for approaches to evalu-
ate such sensitivity is necessary.
The present work is devoted to the analysis 
of the sensitivity of the PBLs of patients with EC to the 
4OHE2 and to the evaluation of the repair efficiency 
of 4OHE2-induced DNA damage.
MATERIALS AND METHODS
The study was performed on the PBLs of 53 EC pa-
tients (stage I–II) with a histologically confirmed di-
agnosis of endometrioid carcinoma. All EC patients 
underwent surgery at the Department of Gyneco-
logical Oncology of the National Cancer Institute, 
Kyiv, Ukraine. As controls PBLs from 20 healthy 
women were used. The mean age of EC patients was 
58.6 ± 3.4 years, healthy controls — 51.1 ± 6.9 years. 
All women provided informed consent for participa-
tion in the study that was approved by the Committee 
for Ethical Issues of the R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology, 
National Academy of Sciences of Ukraine.
All EC patients were interviewed to reveal their 
family history (FH) of cancer, in particular, occurrence 
of malignancy in the family, type of tumor and the 
age at diagnosis of the affected family member. The 
criteria for referring of the EC patients to the group 
of individuals with a FH of cancer was the presence 
of malignant tumors of female reproductive system and 
other Lynch-associated tumors in first and second-
degree relatives.
Lymphocytes were isolated from the peripheral 
blood of patients by centrifugation in a density gradi-
ent of Ficoll-Hypaque. DNA damage analysis was per-
formed by alkaline comet assay as described by us ear-
lier [19]. The level of DNA damage was expressed as the 
percentage of DNA in the comet tails (% tail DNA), which 
was determined using the Comet Score program (TriTek 
Corp., Sumerduck, VA, USA). In order to determine the 
optimal conditions for analyzing the sensitivity of PBLs 
to the 4OHE2, the selection of 4OHE2 concentration 
in ethanol and the time for incubation in RPMI me-
dium with 4OHE2 was performed. It was revealed that 
the most appropriate is the incubation of PBLs with 
4OHE2 at a concentration of 15 μM for 17 h. Cell viability 
was at least 90%, as measured by trypan blue exclusion. 
The level of baseline DNA damage was assessed in the 
PBLs, which were incubated in RPMI medium without 
4OHE2. The net-level of induced DNA damage was 
determined by subtracting the baseline% tail DNA from 
the% tail DNA obtained after incubating the PBLs with 
4OHE2. To evaluate repair efficiency of 4OHE2-induced 
DNA damage PBLs were washed twice with RPMI 
by centrifugation followed by incubation in fresh RPMI 
medium for 2 h at 37 °C. DNA repair efficiency (DRE) was 
estimated as the percent of eliminated DNA damage 
relative to their induced level as described by Savina 
et al. [20] in the following modification:
DRE = [(% tail DNA after 4OHE2 treatment — % tail  
DNA after repair)/% tail DNA after 4OHE2 treatment] × 100%,
where % tail DNA after 4OHE2 treatment is % tail DNA after 
17 h of PBLs incubation in RPMI with 4OHE2; % tail 
DNA after repair is % tail DNA after washing PBLs with RPMI 
and incubation in fresh RPMI medium.
All data were analyzed using the Statistica 8.0 soft-
ware package (StatSoft, Inc.). Nonparametric Mann — 
Whitney U-test was used to compare differences 
between the examined groups. A p-value less than 
0.05 was considered statistically significant.
RESULTS
It was found that the level of baseline DNA damage 
varied significantly both in EC patients (1.1–20.5% tail 
DNA) and in healthy donors (1.5–9.2% tail DNA). When 
comparing the mean values, significantly higher level 
of baseline DNA damage was observed in the PBLs 
of EC patients (7.9 ± 1.0% tail DNA) than in PBLs of the 
control group (3.8 ± 0.5% tail DNA) (p < 0.05) (Table 1). 
Photographic images of DNA comets reflecting the 
levels of baseline DNA damage in PBLs of EC patients 
are presented in Fig. 1, a.
Table 1. Characterization of DNA damage and repair in PBLs of EC pa-
tients and healthy donors
Group of exam-
ined women
Level of baseline 
DNA damage, % tail 
DNA (mean ± SE)
Net-level of 4ОНЕ2-
induced DNA dam-
age, % tail DNA
(mean ± SE)
DNA re-
pair efficien-
cy, % (mean 
± SE)
Healthy donors 3.8 ± 0.5 22.3 ± 2.3 48.8 ± 4.5
EC patients 7.9 ± 1.0* 32.0 ± 2.2* 34.0 ± 4.5*
Note: *significantly different from healthy donors (р < 0.05).
After incubation with 4OHE2, a large heteroge-
neity was observed in the amount of induced DNA 
Fig. 1. Representative DNA comet images obtained from PBLs of EC patients: a — baseline DNA damage; b — 4OHE2-induced 
DNA damage; c — DNA damage remained after repair
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damage in lymphocytes of EC patients (8.1–57.8% 
tail DNA) and healthy donors (7.9–46.8% tail DNA). 
The average level of 4OHE2-induced DNA damage 
was equal to 32.0 ± 2.2% tail DNA in patients with EC, 
while in healthy women it was significantly lower — 
22.3 ± 2.3% tail DNA (p < 0.05). DNA comet images 
representing 4OHE2-induced DNA damage in PBLs 
of EC patients are shown in Fig. 1, b.
Analysis of the repair efficiency of DNA damage 
caused by 4OHE2 showed that the PBLs of EC patients 
have a wider range of this parameter (1.3–91.2% 
tail DNA) than the lymphocytes of healthy do-
nors (7.1–69.8% tail DNA). When comparing the 
average values of the DNA repair efficiency, sig-
nificantly lower level of repair was observed in PBLs 
of EC patients (34.0 ± 4.5%) compared to healthy 
women (48.8 ± 4.5%) (p < 0.05). Photographic images 
of DNA comets representing DNA damage remained 
after repair in PBL of EC patients are given in Fig. 1, c.
The obtained data on the levels of baseline, 
4OHE2-induced DNA damage and DNA repair ef-
ficiency in PBLs were analyzed depending on clinical 
and morphological features of EC patients. It was 
found that none of these parameters was statistically 
associated with the degree of tumor differentiation 
(Table 2). However, there was a tendency to an in-
creased level of baseline DNA damage and decreased 
DNA repair efficiency in EC patients with moderately 
and poorly differentiated tumors. It was shown that 
DNA repair efficiency was significantly lower in PBLs 
of EC patients with deep tumor myometrial invasion 
(> ½ of myometrium) compared to those with less 
invasive tumor (< ½ of myometrium) (22.0 ± 6.5% and 
43.7 ± 6.7, respectively) (p < 0.05). Upon analyzing 
the amount of DNA damage by weight excess, higher 
level of baseline DNA damage was found in PBLs 
of EC patients with body mass index (BMI) more than 
31.0 kg/m2, i.e. in patients with a second and a higher 
obesity degree (9.0 ± 1.4 and 5.6 ± 1.4% tail DNA, 
respectively) (p < 0.05).
Table 2. Analysis of DNA damage and repair in PBLs depending on the 
clinical and morphological characteristics of EC patients
Characteristics  
(percentage of patients)
Level 
of baseline 
DNA dam-
age, % tail 
DNA
(mean ± SE)
Net-level 
of 4ОНЕ2-
induced DNA 
damage, % 
tail DNA
(mean ± SE)
DNA repair 
efficiency, %
(mean ± SE)
Tumor dif-
ferentiation 
grade
Well differentiat-
ed (18.9%)
5.1 ± 1.0 39.1 ± 6.1 41.1 ± 13.1
Moderate-
ly differentiated 
(43.3%)
7.9 ± 1.5 34.2 ± 3.2 30.9 ± 5.7
Poorly differenti-
ated (37.8%)
9.5 ± 2.5 30.3 ± 3.8 34.2 ± 8.7
Depth 
of myome-
trial invasion
< ½ (60.4%) 6.8 ± 1.3 34.3 ± 3.4 43.7 ± 6.7
> ½ (39.6%) 9.7 ± 2.8 26.4 ± 3.7 22.0 ± 6.5**
BMI < 31.0 (50.9%) 5.6 ± 1.4 33.0 ± 3.9 22.8 ± 8.3
> 31.0 (49.1%) 9.0 ± 1.4* 31.6 ± 2.8 36.7 ± 5.4
Notes: *significantly different from EC patients with BMI < 31.0 (р < 0.05). 
**Significantly different from EC patients with depth of tumor invasion 
< ½ of myometrium (р < 0.05).
According to interview results, familial clustering 
of cancers of the female reproductive system and 
gastrointestinal tract was identified in 27% EC patients, 
on the basis of which these women were referred 
to a group with a FH of cancer. There were no sig-
nificant association between the level of baseline and 
4OHE2-induced DNA damage in PBL and the presence 
of a FH in EC patients. At the same time, DNA repair 
efficiency was significantly lower in patients with a FH 
(20.9 ± 7.8%) than in patients with sporadic tumors 
(47.1 ± 5.5%) (p < 0.05) (Fig. 2).
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Fig. 2. Comparison of DNA repair efficiency of 4OHE2-induced 
DNA damage in PBLs between EC patients with no FH (a) and 
with a FH (b)
DISCUSSION
The data presented indicate the genome de-
stabilization in PBLs of EC patients in terms of the 
amount of baseline DNA damage, the sensitivity to the 
4OHE2 and the repair efficiency of 4OHE2-induced 
DNA damage. This agrees with the results obtained 
by us, as well as with the data of other researchers 
on the state of lymphocytes of patients with tumors 
of different origin [4–7]. Among the possible causes 
of genetic instability in PBLs, authors consider the ef-
fect of exogenous and endogenous factors, hereditary 
and acquired defects in repair systems, as well as the 
effect of reactive substances released into the blood 
due to metabolic processes in the tumor.
The results of this study indicate that the level 
of genome instability in the cells of EC patients may 
increase under the influence of estrogen metabolite 
4OHE2. It is known that during metabolism, estrogens 
are converted into a series of intermediate products — 
2-hydroxy-, 16-hydroxy- and 4-hydroxyestrogens [11]. 
According to a number of studies, in patients with 
hormone-dependent tumors, there is an imbalance 
of different types of catechol estrogens and the 
prevalence of 4OHE2 among them, which has the most 
pronounced genotoxic properties [12, 21]. It can be as-
sumed that the increased level of baseline DNA dam-
age in PBLs of the majority of EC patients may reflect 
the elevated content of 4OHE2 in their blood. In ad-
dition, according to our data, an increased amount 
of baseline DNA damage is observed in patients with 
obesity, which is possibly associated with the estrogen 
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synthesis in adipose tissue. In addition, it is possible 
that one of the reasons for the increased amount 
of baseline DNA damage is the hypersensitivity of PBLs 
to the genotoxic effect of 4OHE2 and a reduced repair 
efficiency of 4OHE2-induced DNA damage.
A number of studies have indicated that the level 
of cell sensitivity to the influence of 4OHE2 is deter-
mined by polymorphisms of genes whose products are 
involved in the metabolism of steroid hormones [22–
24]. These include cytochromes CYP 1A1 and 
CYP 1B1, which catalyze the conversion of estrogens 
to catechol estrogens, as well as catechol-o-meth-
yltransferase (COMT) and glutathione-S-transfer-
ase 1 (GSTP1), responsible for the final stages of inac-
tivation of estrogen. It was shown that the polymorphic 
variants of the genes CYP 1A1*2C, CYP 1B1*3, COMT 
Val158Met and GSTP1 Ile105Val are associated with 
an increased amount of the 4OHE2 in leukocytes com-
pared to cells carrying wild-type alleles [22]. Along with 
this, the presence of the CYP 1B1*3 Leu432Val isoform 
is associated with the risk of developing several types 
of cancer, including EC [23]. Furthermore, it has been 
shown that an increased level of chromosomal lesions 
in PBLs of breast cancer patients with polymorphic 
variant of COMT Val158Met is observed [24].
It should also be noted that increased sensitivity 
to the 4OHE2 may be caused by impairments of DNA 
repair systems that are responsible for the recovery 
of oxidative DNA damage arising under the influ-
ence of reactive oxygen species during metabolic 
transformations of estrogens. The reduced repair ef-
ficiency of 4OHE2-induced DNA damage we found 
in EC patients with deep tumor myometrial invasion 
suggests that a low level of repair may be one of the 
factors determining the tumor progression. The data 
obtained in the present work confirm our previous 
studies, according to which the PBLs of EC patients are 
characterized by low repair efficiency of DNA damage 
induced by bleomycin, the genotoxic effect of which, 
like the 4OHE2, is associated with the reactive oxygen 
species generation [4].
The important role of DNA repair in determining 
sensitivity to estrogen metabolites was observed 
by several other authors. Thus, Mizutani A et al. [25] re-
ported on hypersensitivity of the B-lymphocyte cell line 
with defects of DNA repair systems to 4OHE2, which 
is manifested by an increased number of chromosomal 
aberrations. In addition, it has been shown that the 
risk of endometrial and breast cancers is determined 
by the polymorphism in genes of base (XRCC1, OGG1) 
and nucleotide (ERCC2, ERCC4 and ERCC5) excision 
DNA repair [26, 27].
It can be assumed that the inheritance of polymor-
phic gene variants associated with low-active forms 
of repair enzymes for oxidative DNA damage may 
determine the predisposition to hormone-dependent 
tumors. Perhaps, this explains the reduced repair 
efficiency of 4OHE2-induced DNA damage in EC pa-
tients with a FH. It should be noted that in our previous 
study using bleomycin as an inducer of DNA damage, 
low repair efficiency in EC patients with a FH was also 
noted [4].
The obtained results testify to the significant con-
tribution of the estrogen metabolite 4OHE2 influence 
to the evolving of genome destabilization in PBLs 
of EC patients. Decreased repair efficiency of 4-OHE2-
induced DNA damage in PBLs of EC patients with 
a FH indicates a possible pathogenetic relationship 
between the peculiarities of the estrogen metabolism 
in women and a hereditary predisposition to hormone-
dependent cancers. It is possible that tumors arising 
against the background of hereditary genome insta-
bility may have their own phenotypic characteristics, 
different from sporadic neoplasms, in which genetic 
instability occurs under the influence of exogenous 
factors. To date, this issue remains poorly studied, 
however, there are the data suggesting certain phe-
notypic features of tumor associated with expression 
of protein regulators of the cell cycle in EC patients with 
a FH [28]. Therefore, the identification of the molecular 
basis for the genome instability in PBLs of EC patients 
at different levels of its evolving requires further re-
search. The results of such studies will contribute to the 
understanding of hormonal carcinogenesis, revealing 
the mechanisms of interaction between the tumor and 
the host cells and developing practical approaches for 
correcting the EC treatment.
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